Evidence map›Paper›PMID 31751810›Full record

ArticleActa biomaterialia2020

Functional role of glycosaminoglycans in decellularized lung extracellular matrix.

Franziska E Uhl, Fuming Zhang, Robert A Pouliot, Juan J Uriarte, Sara Rolandsson Enes, Xiaorui Han, Yilan Ouyang, Ke Xia, Gunilla Westergren-Thorsson, Anders Malmström and 3 more

Open access · greenAbstract read
In one paragraph

Article in Acta biomaterialia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 103 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Franziska E UhlUniversity of Vermont, Larner College of Medicine, Burlington, VT, United States; Department of Experimental Medical Science, Faculty of Medicine, Lund University, Lund, Sweden.
Fuming ZhangCenter for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY, United States.
Robert A PouliotUniversity of Vermont, Larner College of Medicine, Burlington, VT, United States.
Juan J UriarteUniversity of Vermont, Larner College of Medicine, Burlington, VT, United States.
Sara Rolandsson EnesUniversity of Vermont, Larner College of Medicine, Burlington, VT, United States; Department of Experimental Medical Science, Faculty of Medicine, Lund University, Lund, Sweden.
Xiaorui HanCenter for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY, United States.
Yilan OuyangCenter for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY, United States.
Ke XiaCenter for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY, United States.
Gunilla Westergren-ThorssonDepartment of Experimental Medical Science, Faculty of Medicine, Lund University, Lund, Sweden.
Anders MalmströmDepartment of Experimental Medical Science, Faculty of Medicine, Lund University, Lund, Sweden.
Oskar HallgrenDepartment of Experimental Medical Science, Faculty of Medicine, Lund University, Lund, Sweden.
Robert J LinhardtCenter for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY, United States.
Daniel J WeissUniversity of Vermont, Larner College of Medicine, Burlington, VT, United States. Electronic address: daniel.weiss@uvm.edu.
Rensselaer Polytechnic Institute · USUniversity of Vermont · USLund University · SE

Funding

Vermont INBRE Administrative Supplement 2024 AWD 118P20GM103449 · NIGMS · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI CHRISTOPHER S FRANCKLYN · 2012 to 2026
$58.4M
Multidisciplinary Training in Lung BiologyT32HL076122 · NHLBI · UNIVERSITY OF VERMONT &ST AGRIC COLLEGE · PI IRVIN, CHARLES G, POYNTER, MATTHEW E · 2004 to 2023
$6.1M
Endothelial glycocalyx reconstitution during sepsisR01HL125371 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI LINHARDT, ROBERT J, SCHMIDT, ERIC PETER · 2014 to 2018
$3.4M
The role ofglycosaminoglycan N-sulfation in glomerular biology/pathobiologyR01DK111958 · NIDDK · LOUISIANA STATE UNIV HSC SHREVEPORT · PI MCCARTHY, KEVIN JOHN · 2017 to 2021
$2.6M
Heparan sulfate in neurophysiology and neurological disordersR01NS088496 · NINDS · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI YAMAGUCHI, YU · 2015 to 2018
$1.7M
An Automated Platform for the CE-MS Analysis of GlycosaminoglycansU01CA231074 · NCI · UNIVERSITY OF GEORGIA · PI AMSTER, I JONATHAN · 2018 to 2020
$895k
NCI NIH HHS U01 CA231074NHLBI NIH HHS R01 HL125371NHLBI NIH HHS T32 HL076122NIDDK NIH HHS R01 DK111958NIGMS NIH HHS P20 GM103449NINDS NIH HHS R01 NS088496
6 · The paper itself

Abstract

Despite progress in use of decellularized lung scaffolds in ex vivo lung bioengineering schemes, including use of gels and other materials derived from the scaffolds, the detailed composition and functional role of extracellular matrix (ECM) proteoglycans (PGs) and their glycosaminoglycan (GAG) chains remaining in decellularized lungs, is poorly understood. Using a commonly utilized detergent-based decellularization approach in human autopsy lungs resulted in disproportionate losses of GAGs with depletion of chondroitin sulfate/dermatan sulfate (CS/DS) > heparan sulfate (HS) > hyaluronic acid (HA). Specific changes in disaccharide composition of remaining GAGs were observed with disproportionate loss of NS and NS2S for HS groups and of 4S for CS/DS groups. No significant influence of smoking history, sex, time to autopsy, or age was observed in native vs. decellularized lungs. Notably, surface plasmon resonance demonstrated that GAGs remaining in decellularized lungs were unable to bind key matrix-associated growth factors FGF2, HGF, and TGFβ1. Growth of lung epithelial, pulmonary vascular, and stromal cells cultured on the surface of or embedded within gels derived from decellularized human lungs was differentially and combinatorially enhanced by replenishing specific GAGs and FGF2, HGF, and TGFβ1. In summary, lung decellularization results in loss and/or dysfunction of specific GAGs or side chains significantly affecting matrix-associated growth factor binding and lung cell metabolism. GAG and matrix-associated growth factor replenishment thus needs to be incorporated into schemes for investigations utilizing gels and other materials produced from decellularized human lungs. STATEMENT OF SIGNIFICANCE: Despite progress in use of decellularized lung scaffolds in ex vivo lung bioengineering schemes, including use of gels and other materials derived from the scaffolds, the detailed composition and functional role of extracellular matrix (ECM) proteoglycans (PGs) and their glycosaminoglycan (GAG) chains remaining in decellularized lungs, is poorly understood. In the current studies, we demonstrate that glycosaminoglycans (GAGs) are significantly depleted during decellularization and those that remain are dysfunctional and unable to bind matrix-associated growth factors critical for cell growth and differentiation. Systematically repleting GAGs and matrix-associated growth factors to gels derived from decellularized human lung significantly and differentially affects cell growth. These studies highlight the importance of considering GAGs in decellularized lungs and their derivatives.

Indexed as

AdultAgedAged, 80 and overBronchiCell Culture TechniquesCell LineCell ProliferationEpithelial CellsExtracellular MatrixFemaleFibroblast Growth Factor 2GlycosaminoglycansHepatocyte Growth FactorHumansMaleMiddle AgedFibroblast Growth Factor 2GlycosaminoglycansHepatocyte Growth FactorHGF protein, humanTransforming Growth Factor beta1COPDDecellularizationExtracellular matrix gelGlycosaminoglycanLungMatrix-associated growth factors

Identifiers

PMID31751810
PMCPMC8713186
OpenAlexW2989571936

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.